Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers.
BACKGROUND
Swellable hydrogel microparticle-based pressurized metered dose inhaler (pMDI) formulations allow delivery of small respirable sized particles (1-5 microns), which swell upon the deposition in the deep lung and therefore can elude alveolar macrophage uptake via their larger geometric sizes. In addition, optimized surface chemistry may allow for sustained release of drug for multiple days.


METHODS
Drug-loaded PLGA nanoparticles encapsulated in PEG/chitosan (Cs) graft copolymer-based hydrogel microparticles were synthesized and characterized. Physical stability of dispersions within Hydrofluoroalkane propellant systems was assessed. The formulations were evaluated for aerosolization performance using a Next Generation Impactor.


RESULTS
Low density PEG/chitosan (Cs) graft copolymer-based hydrogel microparticles containing drug-loaded PLGA nanoparticles has an average diameter of 1-2 μm. These dispersions showed good compatibility with HFA227ea. Suspension stability was found to vary with the concentration of hydrogel particles. It was typically between 1 to 5 min and was found to be easily redispersible. Aerosolization studies showed fine particle fraction as high as 65% could be achieved.


CONCLUSIONS
These swellable hydrogel-based microparticle pMDI formulations could be used as potential delivery vehicles for nanoparticle therapeutics.
Selvam
Parthiban
P
College of Pharmacy, University of Texas at Austin, 1 University Station, Austin, TX 78712, USA. chemparthi@gmail.com
El-Sherbiny
Ibrahim M
IM
Smyth
Hugh D C
HD
D000280:Administration, Inhalation; D000335:Aerosol Propellants / Q000737:chemistry; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D048271:Chitosan / Q000737:chemistry; D003474:Curcumin / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems; D004355:Drug Stability; D006845:Hydrocarbons, Fluorinated / Q000737:chemistry; D020100:Hydrogels; D019344:Lactic Acid / Q000737:chemistry; D008168:Lung / Q000378:metabolism; D036501:Metered Dose Inhalers; D008863:Microspheres; D053758:Nanoparticles; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D005466:Fluorocarbons
D000335:Aerosol Propellants; D000894:Anti-Inflammatory Agents, Non-Steroidal; D048271:Chitosan; D003474:Curcumin; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D006845:Hydrocarbons, Fluorinated; D020100:Hydrogels; D019344:Lactic Acid; D011092:Polyethylene Glycols; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C094049:apaflurane; D005466:Fluorocarbons